Compositions for preserving insulin-producing cells and insulin production and treating diabetes

摘要: Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment autoimmune diabetes-prone, non-obese diabetic (NOD) mice, widely used model Type 1 diabetes (T1D), which resulted diabetes-free state for one year without apparent toxicity the need to use insulin. precipitously reduces accumulation islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death T B derived from NOD mice. attenuated pro-inflammatory cytokine chemokine production immune cells this human T1D. also provides cytoprotection beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery Modifier peptide cSN50.1 can result lowering fasting blood glucose levels may ameliorate (e.g., reduce, eliminate) insulin resistance, compositions, methods described herein be treating 2 (T2D).